VBI Vaccines (VBIV) Getting Favorable News Coverage, Analysis Shows

News articles about VBI Vaccines (NASDAQ:VBIV) have trended positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. VBI Vaccines earned a news sentiment score of 0.29 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.3597241427933 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:

VBI Vaccines (NASDAQ:VBIV) traded up 5.39% on Friday, reaching $3.52. The company had a trading volume of 359,097 shares. The firm’s market capitalization is $141.61 million. VBI Vaccines has a one year low of $2.75 and a one year high of $6.60. The company’s 50 day moving average is $3.77 and its 200-day moving average is $4.53.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research lowered VBI Vaccines from a “buy” rating to a “hold” rating in a research report on Saturday, July 15th. ValuEngine raised VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Noble Financial reaffirmed a “buy” rating on shares of VBI Vaccines in a research note on Monday, July 31st.

COPYRIGHT VIOLATION WARNING: “VBI Vaccines (VBIV) Getting Favorable News Coverage, Analysis Shows” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/28/vbi-vaccines-vbiv-earns-daily-news-impact-rating-of-0-29.html.

In other VBI Vaccines news, CEO Jeff Baxter purchased 10,000 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were purchased at an average cost of $3.22 per share, for a total transaction of $32,200.00. Following the completion of the transaction, the chief executive officer now owns 120,255 shares of the company’s stock, valued at approximately $387,221.10. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders acquired 23,000 shares of company stock valued at $74,510 in the last ninety days. 54.50% of the stock is owned by corporate insiders.

About VBI Vaccines

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Insider Buying and Selling by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply